Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Acta Neuropathol Commun ; 7(1): 59, 2019 04 25.
Artículo en Inglés | MEDLINE | ID: mdl-31023364

RESUMEN

BACKGROUND: Diffuse lower WHO grade II and III gliomas (LGG) are slowly progressing brain tumors, many of which eventually transform into a more aggressive type. LGG is characterized by widespread genetic and transcriptional heterogeneity, yet little is known about the heterogeneity of the DNA methylome, its function in tumor biology, coupling with the transcriptome and tumor microenvironment and its possible impact for tumor development. METHODS: We here present novel DNA methylation data of an LGG-cohort collected in the German Glioma Network containing about 85% isocitrate dehydrogenase (IDH) mutated tumors and performed a combined bioinformatics analysis using patient-matched genome and transcriptome data. RESULTS: Stratification of LGG based on gene expression and DNA-methylation provided four consensus subtypes. We characterized them in terms of genetic alterations, functional context, cellular composition, tumor microenvironment and their possible impact for treatment resistance and prognosis. Glioma with astrocytoma-resembling phenotypes constitute the largest fraction of nearly 60%. They revealed largest diversity and were divided into four expression and three methylation groups which only partly match each other thus reflecting largely decoupled expression and methylation patterns. We identified a novel G-protein coupled receptor and a cancer-related 'keratinization' methylation signature in in addition to the glioma-CpG island methylator phenotype (G-CIMP) signature. These different signatures overlap and combine in various ways giving rise to diverse methylation and expression patterns that shape the glioma phenotypes. The decrease of global methylation in astrocytoma-like LGG associates with higher WHO grade, age at diagnosis and inferior prognosis. We found analogies between astrocytoma-like LGG with grade IV IDH-wild type tumors regarding possible worsening of treatment resistance along a proneural-to-mesenchymal axis. Using gene signature-based inference we elucidated the impact of cellular composition of the tumors including immune cell bystanders such as macrophages. CONCLUSIONS: Genomic, epigenomic and transcriptomic factors act in concert but partly also in a decoupled fashion what underpins the need for integrative, multidimensional stratification of LGG by combining these data on gene and cellular levels to delineate mechanisms of gene (de-)regulation and to enable better patient stratification and individualization of treatment.


Asunto(s)
Neoplasias Encefálicas/genética , Metilación de ADN/genética , Dosificación de Gen , Glioma/genética , Transcriptoma , Neoplasias Encefálicas/complicaciones , Biología Computacional , Epigénesis Genética , Humanos , Clasificación del Tumor , Microambiente Tumoral/genética , Organización Mundial de la Salud
2.
Ann Oncol ; 29(6): 1431-1436, 2018 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-29617713

RESUMEN

Background: The vascular endothelial growth factor antibody bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in many countries including the USA and Switzerland, but not the European Union, in 2009. Here, we explored the hypothesis that the approval of bevacizumab improved outcome with glioblastoma on a population level. Patients and methods: The prognostic significance of epidemiological, molecular genetic, and clinical data including treatment for glioblastoma patients diagnosed from 2010 to 2014 in the Canton of Zurich, Switzerland, was retrospectively analyzed using log-rank test and Cox proportional hazards models. Data were compared with data for the years 2005-2009. Results: In total, 310 glioblastoma patients were identified in the years 2010-2014. Median overall survival was 13.5 months for patients with known isocitrate dehydrogenase (IDH) wild-type (wt) (IDH1R132H-non-mutant) tumors (N = 248), compared with 11.3 months for IDH wt patients (P = 0.761) before (2005-2009). In the IDH wt cohort, bevacizumab use at any time increased from 19% in 2005-2009 to 49% in 2010-2014. Multivariate analysis did not identify bevacizumab exposure at any time to be associated with survival. Yet, upon the second-line treatment, baseline doses of corticosteroids were reduced by more than half in 83% of patients on bevacizumab compared with 48% of the patients treated with bevacizumab-free regimens (P = 0.007). Conclusion: This epidemiological study of a small, but clinically well-annotated patient cohort fails to support the assumption that the strong increase of bevacizumab use since 2010 improved survival in glioblastoma although clinical benefit associated with decreased steroid use may have been achieved.


Asunto(s)
Antineoplásicos Inmunológicos/uso terapéutico , Bevacizumab/uso terapéutico , Neoplasias Encefálicas/mortalidad , Glioblastoma/mortalidad , Calidad de Vida , Anciano , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/patología , Femenino , Estudios de Seguimiento , Glioblastoma/tratamiento farmacológico , Glioblastoma/patología , Humanos , Masculino , Pronóstico , Estudios Retrospectivos , Tasa de Supervivencia
3.
Oncogene ; 35(25): 3260-71, 2016 06 23.
Artículo en Inglés | MEDLINE | ID: mdl-26500056

RESUMEN

Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming growth factor (TGF)-ß represents a central mediator of the malignant phenotype of these tumors by promoting invasiveness and angiogenesis, maintaining tumor cell stemness and inducing profound immunosuppression. Integrins, which are highly expressed in glioma cells, interact with the TGF-ß pathway. Furthermore, a link has been described between activity of the transcription factor aryl hydrocarbon receptor (AhR) and TGF-ß expression. Here we demonstrate that integrin inhibition, using αv, ß3 or ß5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or pharmacological inhibition by the cyclic RGD peptide EMD 121974 (cilengitide) or the non-peptidic molecule GLPG0187, inhibits AhR activity. These effects are independent of cell detachment or cell density. While AhR mRNA expression was not affected by integrin inhibition, AhR total and nuclear protein levels were reduced, suggesting that integrin inhibition-mediated regulation of AhR may occur at a post-transcriptional level. AhR-null astrocytes, AhR-null hepatocytes or glioblastoma cells with a transiently silenced AhR gene showed reduced sensitivity to integrin inhibition-mediated alterations in TGF-ß signaling, indicating that AhR mediates integrin control of the TGF-ß pathway. Accordingly, there was a significant correlation of αv integrin levels with nuclear AhR and pSmad2 levels as determined by immunohistochemistry in human glioblastoma in vivo. In summary, this study identifies a signaling network comprising integrins, AhR and TGF-ß and validates integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to block AhR- and TGF-ß-controlled features of malignancy in human glioblastoma.


Asunto(s)
Neoplasias Encefálicas/metabolismo , Glioblastoma/metabolismo , Integrinas/metabolismo , Receptores de Hidrocarburo de Aril/metabolismo , Transducción de Señal , Factor de Crecimiento Transformador beta/metabolismo , Animales , Animales Recién Nacidos , Anticuerpos Neutralizantes/farmacología , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Línea Celular Tumoral , Células Cultivadas , Glioblastoma/genética , Glioblastoma/patología , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Immunoblotting , Inmunohistoquímica , Integrinas/antagonistas & inhibidores , Integrinas/genética , Ratones Endogámicos C57BL , Ratones Noqueados , Naftiridinas/farmacología , Péptidos Cíclicos/farmacología , Interferencia de ARN , Receptores de Hidrocarburo de Aril/antagonistas & inhibidores , Receptores de Hidrocarburo de Aril/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Venenos de Serpiente/farmacología , Sulfonamidas/farmacología , Factor de Crecimiento Transformador beta/genética
4.
J Neurooncol ; 117(1): 25-32, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24395351

RESUMEN

There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1, codeletion of 1p/19q and promoter hypermethylation of O (6) -methylguanine-DNA-methyltransferase. More importantly, there is limited translation of these factors into clinical practice. The cancer genome atlas data and also clinical correlative analyses suggest a pivotal role for the epidermal growth factor receptor /protein kinase B/mammalian target of rapamycin (mTOR) pathway in both biology and the clinical course of gliomas. However, attempts to stratify gliomas by activating alterations in this pathway have failed thus far. The tumors of 40 patients with WHO grade II gliomas without immediate postoperative genotoxic treatment and known progression and survival status at a median follow-up of 12.2 years were analyzed for expression of the mTOR complex 2 downstream target N-myc downstream regulated gene (NDRG)1 using immunohistochemistry. Baseline characteristics for NDRG1 absent/low versus moderate/high patients were similar. Time to reintervention was significantly longer in the NDRG1 group (P = 0.026). NDRG1 may become a novel biomarker to guide the decision which WHO°II glioma patients may be followed without postsurgical intervention and which patients should receive genotoxic treatment early on. Validation of this hypothesis will be possible with the observational arm of the RTOG 9802 and the pretreatment step of the EORTC 22033/26032 trials.


Asunto(s)
Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/metabolismo , Proteínas de Ciclo Celular/metabolismo , Glioma/diagnóstico , Glioma/metabolismo , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Adulto , Anciano , Astrocitoma/diagnóstico , Astrocitoma/metabolismo , Astrocitoma/patología , Astrocitoma/terapia , Biomarcadores de Tumor/metabolismo , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Estudios de Seguimiento , Glioma/patología , Glioma/terapia , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Clasificación del Tumor , Oligodendroglioma/diagnóstico , Oligodendroglioma/metabolismo , Oligodendroglioma/patología , Oligodendroglioma/terapia , Pronóstico , Estudios Prospectivos , Retratamiento , Análisis de Supervivencia , Factores de Tiempo
5.
Oncogene ; 28(28): 2593-605, 2009 Jul 16.
Artículo en Inglés | MEDLINE | ID: mdl-19465936

RESUMEN

The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and transforming growth factor-beta (TGF-beta) signaling. As TGF-beta is an important mediator of the malignant phenotype of human gliomas, we studied AhR expression and function in glioma cells. AhR was not only expressed in glioma cells in vitro, but was also detected in human gliomas in vivo by immunohistochemistry, with a predominantly nuclear staining in glioblastomas. The AhR agonist, 3-methylcholanthrene, induced AhR nuclear translocation and upregulated mRNA levels of the AhR target gene, cytochrome P450 1A1 (CYP1A1). Conversely, pharmacological inhibition of AhR using the novel AhR antagonist, CH-223191, or AhR gene silencing using small interfering RNA showed that constitutive AhR activity positively controls TGF-beta1, TGF-beta2 and latent TGF-beta-binding protein-1 protein levels in malignant glioma cells. Moreover, antagonism of AhR reduced clonogenic survival and invasiveness of glioma cells. In contrast, AhR regulates TGF-beta signaling negatively in non-neoplastic astrocytes. Thus, the pathogenesis of glioma formation may involve altered AhR regulation of the TGF-beta/Smad pathway, and AhR may represent a promising target for the treatment of human malignant gliomas and other diseases associated with pathological TGF-beta activity.


Asunto(s)
Neoplasias Encefálicas/metabolismo , Regulación hacia Abajo , Glioblastoma/metabolismo , Receptores de Hidrocarburo de Aril/antagonistas & inhibidores , Proteínas Smad/fisiología , Factor de Crecimiento Transformador beta/fisiología , Línea Celular Tumoral , Silenciador del Gen , Humanos , Inmunohistoquímica , Reacción en Cadena de la Polimerasa , ARN Mensajero/genética , Receptores de Hidrocarburo de Aril/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA